17 Febr. 2022. As part of the “Strategy to Achieve Global COVID-19 Vaccination by mid-2022”, global targets of 40% population coverage by end of 2021 and 70% coverage by June 2022 have been set by the World Health Organization (WHO), to successfully prevent severe illness and deaths, minimize so...cial disruption and economic consequences of COVID-19, curtail the emergence of new SARS-CoV-2 variants of concern (VOCs) and ultimately control the pandemic.
more
O SAGE aplica os princípios da medicina baseada em evidências e estabeleceu um processo metodológico completo para emitir ou atualizar recomendações. Especificamente para vacinas contra a COVID-19, uma descrição detalhada dos processos metodológicos pode ser encontrada no esquema de evidênc...ias do SAGE para vacinas contra a COVID-19. Esse esquema contém orientações sobre como levar em consideração os dados provenientes de ensaios clínicos em apoio à emissão de recomendações baseadas em evidências específicas para vacinas.
more
COVID-19 Situation Update OPS/WHO Argentina: 10 February 2022
Situation report generated by the OPS/WHO representation in Argentina
The Lancet Volume June 2020, vol.4 : e217-218
(Первинна та бустерна вакцинації) – з векторною вакциною – (вакцина Janssen® від COVID-19 виробництва Janssen Cilag International/Johnson & Johnson
Станом на: 14 лютого 2022 р. (даний інформаційн...й лист постійно оновлюється)
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019)
(Grundimmunisierung und Auffrischimpfungen) – mit Vektor-Impfstoff – (COVID-19 Vaccine Janssen® von Janssen Cilag International/Johnson & Johnson)
Stand: 14. Februar 2022 (dieses Aufklärungsmerkblatt wird laufend aktualisiert)
more
– з вакциною на білковій основі
(Nuvaxovid® виробництва Novavax)
Станом на: 15 лютого 2022 р. (даний інформаційний лист постійно оновлюється)
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Cor...ona Virus Disease 2019) (Grundimmunisierung )
– mit proteinbasiertem Impfstoff –
(Nuvaxovid® von Novavax)
Stand: 15. Februar 2022 (dieser Aufklärungsbogen wird laufend aktualisiert)
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more
Technical guidelines for testing for COVID-19 in the clinical laboratories of the National Integrated Health System.
Biodiversity and healthy natural ecosystems, including protected areas in and around cities, provide ecosystem benefits and services that support human health, including reducing flood risk, filtering air pollutants, and providing a reliable supply of clean drinking water. These services help to red...uce the incidence of infectious diseases and respiratory disorders, and assist with adaptation to climate change. Access to nature offers many other direct health benefits, including opportunities for physical activity, reduction of developmental disorders and improved mental health.
more
Wearing a face mask can help reduce the spread of COVID-19 in the community by reducing the release of respiratory droplets from asymptomatic / pre-symptomatic individuals or those with mild non-specific symptoms. The use of face masks for this purpose may be adopted to reduce the societal impact as...sociated with absence from work or healthcare pressures due to infection, or to protect vulnerable individuals in particular settings.
more
El presente material es un aporte NO OFICIAL y volutario realizado a partir de la reunión clínica del equipo de Infectología Pediátrica PUC. Su objetivo
de aportar con un recurso educativo que contribuya a la actualización de los profesionales y estudiantes de la salud respecto a este problem...a de salud global.
La pandemia por SARS-CoV2 es una amenaza respecto a la cual existe un flujo de información en permanente y rápido cambio. Complemente siempre su lecturas con fuentes actualizadas.
more
This document provides interim guidance to countries on testing considerations and strategies for suspect cases of severe acute hepatitis of unknown aetiology in children. It is primarily intended for clinical, programmatic, laboratory and diagnostic stakeholders across Member States and national pu...blic health authorities involved in the identification and investigation of cases of severe acute hepatitis in children.
This document is part of a package of guidance for this event, which includes suggested minimum reporting variables and a clinical Case Report Form support Member States with case investigation and reporting.
more
In a retrospective review of hospital records of 40 human monkeypox cases from Nigeria, the majority developed fever and self-limiting vesiculopustular skin eruptions. Five deaths
were reported. Compared to human immunodeficiency virus (HIV)–negative cases, HIV type 1–coinfected cases had more ...prolonged illness, larger lesions, and higher rates of both secondary bacterial skin infections and genital ulcers.
more
This document contains summary information on the latest projections from the IHME model on COVID-19 in Peru. The model was run on July 15, 2022, with data through July 10, 2022.